-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $115

Benzinga·11/10/2025 14:47:28
Listen to the news
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $114 to $115.